Freeze and fight: new combo therapy aims to extend lung cancer survival
NCT ID NCT04339218
First seen Jan 31, 2026 · Last updated May 01, 2026 · Updated 11 times
Summary
This study tests whether freezing a tumor (cryoablation) alongside standard immunotherapy and chemotherapy helps people with advanced lung cancer live longer. About 214 adults with metastatic lung adenocarcinoma will be randomly assigned to receive either the standard drug combo alone or the standard drugs plus the freezing procedure. The main goal is to see if adding cryoablation improves survival at one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Institut Bergonié
RECRUITINGBordeaux, Gironde, 33076, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.